Therefore, it is particularly compelling to realise how HT affects these two significant targets of cancer immune evasion mechanisms (PD-L1 and NLRC5) when considering the integration of HT into immunotherapy strategies for treating ovarian cancer. Here, NLRC5 is linked to cancer.